ACOG News
Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented...
Business Wire
Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented...
Business Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Companys Board of Directors (the...
Business Wire
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL(Benzgalantamine) Use in Long-Term Care
Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE...
Business Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Companys Board of Directors (the...
Business Wire
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on August 31st, 2026, the Compensation Committee of the Companys Board of Directors (the...
Business Wire
Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. We are...
Business Wire
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +5.71% and +3.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks